Hormone Resistant Prostate Cancer Completed Phase 2 Trials for Tivantinib (DB12200)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01519414Tivantinib in Treating Patients With Metastatic Prostate CancerTreatment